Clinical trial
A Phase I/Ⅱa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A830 in Solid Tumors
NCT07718581 is registered in ClinicalTrials.gov with Hutchmed as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/Ⅱa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A830 in Solid Tumors
- Lead sponsor
- Hutchmed
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- September 24, 2026
- Completion date
- December 15, 2029
- Enrollment
- 147 (estimated)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumor, adult